Type of information: Termination of an agreement
Company: Zealand Pharma (Denmark) Helsinn Healthcare (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: termination of an agreement
Action mechanism: Glucagon-like Peptide (GLP) analogue. Elsiglutide is a novel GLP-2 peptide receptor agonist, invented by Zealand and licensed globally to Helsinn in 2008 for its therapeutic use in Cancer Supportive Care.
Disease: chemotherapy-induced diarrhea
Details: • On June 12, 2017, Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, has returned elsiglutide for the treatment of chemotherapy-induced diarrhea to Zealand, thereby concluding the licence agreement between the companies. Elsiglutide is a novel GLP-2 peptide analogue invented by Zealand that was licensed globally to Helsinn in 2008 for use in cancer-supportive care. Elsiglutide was licensed to Helsinn to conduct and finance all clinical development and commercialization, and Zealand was eligible to receive milestone payments and royalties on global sales. As of today, the license agreement will no longer be active. Zealand will communicate the potential further development of elsiglutide at a later stage, following a thorough evaluation.